Fujian carries out volume procurement for drugs that have not been consistently evaluated
Release date: 2020-01-14 Views: 0
On January 13, Fujian issued a document to carry out volume purchases for drugs that have not been consistently evaluated.
▍Fujian will purchase a quantity of unreviewed drugs
On the afternoon of January 13, the Fujian Medical Security Bureau, the Fujian Provincial Health and Health Committee, and the Fujian Provincial Drug Administration issued the "Notice on Expanding the Scope of Centralized Drug Purchase" (hereinafter referred to as the "Notice").
The "Notice" clearly expands the scope of drugs that are purchased and used in a centralized manner, and implements the procurement of selected drugs with quantity and price-for-quantity.
Expanding the scope of centralized procurement and use of drugs-in accordance with the principles of active, prudent, step-by-step advancement, for some drugs with large purchase amounts, sufficient competition, mature clinical use, and no generic drugs with the same generic name that have passed the consistency evaluation of quality and efficacy The experts are jointly organized by the Provincial Medical Insurance Bureau, the Health and Health Commission, and the Drug Supervision Bureau to select the selected drugs into the scope of centralized volume procurement and implement them in public medical institutions across the province. Encourage the participation of the Fujian military, armed police medical institutions and other medical institutions. .
Purchasing selected drugs with quantity purchase and price-for-quantity—generic medicines that failed to pass the consistency evaluation of quality and efficacy according to the same generic name of public medical institutions in the province last year (excluding reference preparations, passing FDA certification and being sold in Europe and the United States) 70% of the total consumption of the estimated generic basis.
Ensure that the basic quantity is completed within the procurement cycle, and that the amount of selected drugs is in principle not less than 60% of the total use of generic drugs with the same generic name (excluding reference preparations, FDA-approved generic drugs and sales in Europe and the United States). Volume purchase, exchange price.
Explore cross-regional joint development of centralized volume procurement. The pilot procurement cycle will last for one year from the formal implementation of centralized volume procurement.
In addition, the "Notice" also stipulates that the selected drugs are sold at zero margin, and the selected price is used as the medical insurance payment standard within the scope of the medical insurance catalog.
In principle, for other unreviewed drugs under the same general name, the medical insurance fund will settle according to the same payment standards. If the price of the drug used by the patient is significantly higher than the price of the selected drug, the medical insurance payment standard shall be adjusted according to the transition period of 2-3 years. The drug payment shall be settled uniformly by the medical insurance agency.
▍Broadband procurement and expansion of variety, action in multiple places
It is not difficult to see that more and more places are starting to carry out spontaneous practice of volume purchase and variety expansion.
On November 29, the State Council's Leading Group for Deepening the Reform of the Medical and Health System issued the “Notice on Several Policies and Measures to Further Deepen the Reform of the Medical and Health System with Centralized Procurement and Use of Drugs as a Breakthrough”.
The notification requires that for drugs that are not included in the centralized procurement and use scope of the national organization, each locality can learn from the centralized procurement and use experience of the national organization, and adopt separate or cross-regional alliances, etc., in the scope of procurement of drugs, finalist standards, centralized procurement forms, etc. Intensify reform and innovation.
On November 20th, the Hebei Provincial Medicament Collection Center issued a notice to launch centralized procurement of outpatient drugs for "two diseases" (hypertension, diabetes), involving captopril tablets, metformin hydrochloride tablets, glimepiride tablets, and aca 15 kinds of sugar tablets and so on.
It is worth noting that, in this centralized collection in Hebei Province, 9 varieties were selected by pharmaceutical companies that have not been consistently evaluated. According to the provisions of the Hebei Provincial Medicinal Collection Center, the number of pharmaceutical manufacturers under the same generic name is not enough. For three companies, if the drugs that have not passed the consistency evaluation meet the requirements, they can be confirmed to be selected, but the price of the selected drugs needs to be more than 20% lower than the drugs that passed the consistency evaluation.
On November 26, the Jiangxi Provincial People's Government issued the "Implementation Plan for the Purchasing and Use of Drugs in Jiangxi Province", which proposed that-among generic generic drugs corresponding to generic drugs that have never passed consistency evaluations of quality and efficacy, large clinical doses were selected. For drugs with high purchase amounts and sufficient competition, organize the implementation of volume purchases.
Recently, at the symposium on pharmaceutical companies held by the Anhui Medical Insurance Bureau, relevant leaders of the Anhui Medical Insurance Bureau disclosed the implementation plan of "Negotiation of Negotiable Pricing (Pilot) of Certain Commonly Used Drugs and Second Batch of Anticancer Drugs in Public Medical Institutions of Anhui Province"). ".
According to the plan, the amount of drugs purchased in 2018 was antibiotics of public medical institutions in Anhui Province, which are cephalosporin-related drugs, 90% of lipid-lowering chemicals and 80% of the second batch of anti-cancer and anti-tumor chemicals. With volume procurement, according to the clinical medication situation and quality type factors, the catalogue is selected by medical experts.
It is reported that the Anhui Procurement Drug Catalogue has been initially determined, involving a total of 128 drugs.
On January 10, the Hunan Public Resources Trading Service Platform issued a notice that the 52 centralized procurement of special antibacterial drugs will officially enter the quotation link.
According to the relevant documents of Hunan Province, the scope of its procurement is mainly based on the ordering of the pharmaceutical procurement amount of the provincial procurement platform in 2018 from large to small, with the cumulative purchase amount accounting for the top 80% of the antibiotics in the medicines-involving amoxicillin, the United States Losicillin, flucloxacillin, cefdinir, cefuroxime, ceftriaxone, etimicin, azithromycin, levofloxacin, moxifloxacin, clindamycin, fluconazole, and caspofungin.
On January 9th, Wuhan carried out bargaining negotiations for special insulin with volume-the scope of the Wuhan insulin band volume purchase varieties was human insulin and insulin analog drugs that were linked to Wuhan before June 30, 2019 and had a transaction volume at the local hospital. .
There are mainly short-acting insulin, intermediate-acting insulin, pre-mixed insulin, and long-acting insulin; insulin analog drugs are divided into short-acting insulin analogs, intermediate-acting insulin analogs, and long-acting insulin analogs.
It is estimated that 17 million pieces of insulin will be purchased, and the total amount of procurement will be approximately 130 million yuan based on the median price of each group of products.
On-site bargaining companies include Novo Nordisk, Sanofi, Eli Lilly, Gan Li Pharmaceutical, Tonghua Dongbao, Yuheng Pharmaceutical, and Zhuhai Federation.
Earlier, Qinghai Province carried out volume procurement of some antibacterial drugs and key monitored varieties.
In addition to the country's lead-level procurement of drugs with large clinical use and over-consistent evaluation, it is undoubtedly worthy of the attention of pharmaceutical companies. .
- Basic introduction of Heilongjiang Hexiang Pharmaceutical Co., Ltd.
- How to contact Bermuda Medical (Shanghai) Regenerative Medicine Technology Co., Ltd.
- Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Brief introduction of Zaozhuang Yinhai Pharmaceutical Co., Ltd.
- Contact information of Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Introduction of Bermoudi (Shanghai) Regenerative Medicine Technology Co., Ltd.
- Nature子刊：2020年FDA可能批准的新药 1. Nature issue: FDA may approve new drugs in 2020
- “即用型”CAR-T疗法：权宜之计还是未来的发展方向？ 2. "Ready-to-use" CAR-T therapy: an expedient or future direction?
- 2019年全球新上市的重磅创新药盘点 3. Inventory of blockbuster innovative medicines listed globally in 2019
- 2019年12月全球批准新药概况 4. Global Approval of New Drugs in December 2019
- 18种！ 5. 18 types! National Health Commission issued the first batch of key national high-value medical consumables governance list
- 国家药监局发文为亚硝胺类杂质的控制提供指导 6.SFDA issued a document to provide guidance for the control of nitrosamine impurities
- 福建针对未过一致性评价药品开展带量采购 7.Fujian carries out volume procurement for drugs that have not been consistently evaluated